AbbVie
Innovative Drug Developer
In the fields of medical aesthetics and treatment, Botox has consistently been the market leader, with AbbVie and its subsidiary Allergan maintaining their dominant position through this flagship product.
In recent years, Revance's launch of Daxxify has attempted to challenge Botox's market position. However, with AbbVie's victory in the patent defense battle, the scales of this competition seem to have tipped entirely in favor of the pharmaceutical giant.
Patent infringement established
Compensation Amount Linked to Sales Data
According to foreign media reports, a jury in Delaware recently ruled that Revance infringed on three patents owned by AbbVie during the development of its Botox competitor, Daxxify. These patents involve the formulation and production process of Botox, representing the culmination of AbbVie's years of technological accumulation and innovation in this field. As a result, Revance is required to pay $56 million in royalties to AbbVie.
Data shows that Botox, developed by Allergan, an American company, is a type of botulinum toxin A primarily used in medical aesthetics and treating conditions like muscle spasms. Its development began in the 1970s when American ophthalmologist Alan B. Scott started researching the application of botulinum toxin in treating eye diseases and introduced Oculinum, the precursor to Botox.
In 1989, Botox received approval from the U.S. FDA for the treatment of strabismus and blepharospasm among other conditions. In 1991, Allergan acquired the product and officially renamed it Botox. In 2002, Botox gained FDA approval for cosmetic indications such as improving glabellar lines. In terms of sales, Botox is one of the best-selling medical aesthetic products globally, dominating the global botulinum toxin injectable market.
This ruling is undoubtedly a heavy blow for Revance. Not only did the jury reject Revance's claim that the patents were invalid, but it also set different royalty rates for each of the three patents. The rate for one ongoing patent was set at 15%, while the rates for the other two patents, which expired in September 2023, were set at 12% and 4%, respectively. These fees will be paid based on the sales revenue of Revance’s Daxxify product.
Daxxify, developed by Revance Therapeutics, is a long-acting type A botulinum toxin based on its proprietary TransMTs technology platform. In September 2022, Daxxify received FDA approval in the United States for the improvement of glabellar lines in adults. In August 2023, the FDA further approved it for the treatment of cervical dystonia in adults.
Its biggest selling point is the long-lasting effect (claimed to last up to 6 months, longer than Botox's 3-4 months), and it is considered a strong competitor to Botox.
In terms of sales, in 2023, the cumulative annual sales of Daxxify reached 84 million US dollars, and the cumulative revenue for the first three quarters of last year was 79 million US dollars.
In September 2024, Fosun Pharma received authorization for the Chinese version of Daxxify® (English name: Daxxify®, project code: RT002), which was approved for marketing in China. It is used for the temporary improvement of moderate to severe glabellar lines in adults caused by the activity of the corrugator and/or procerus muscles, opening up a new market for the product. With the expansion of indications and market promotion, Daxxify is expected to occupy a more significant position in the botulinum toxin market.
Originally, Revance had high hopes for this product, expecting to gain a significant market share. However, it now has to hand over a substantial portion of its profits to AbbVie, which will have a major impact on its market strategy and financial situation.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Multiple Rounds of Confrontation
The Battle for Market Dominance
The confrontation between AbbVie and Revance was no coincidence. In 2020, AbbVie acquired Allergan for a staggering $63 billion, bringing the flagship product Botox into its portfolio. Shortly after, in 2021, AbbVie filed its first lawsuit against Revance, demanding "reasonable royalty fees and lost profits," demonstrating its strong defense of market dominance.
In 2023, the conflict between the two parties further escalated. AbbVie sued Revance again, accusing it of stealing trade secrets by poaching core employees, and stated that Revance's competitive tactics were "desperate measures" and "taking shortcuts through the misappropriation of trade secrets."
Notably, Revance was acquired by Crown Laboratories for $924 million in August last year. This legal defeat undoubtedly adds pressure to its subsequent development and indirectly reflects the competitive challenges rival companies face against the patent barriers of leading products.
A series of litigation actions also highlight AbbVie's high regard for the intellectual property of Botox — since becoming a blockbuster product in 2006, Botox has maintained strong growth momentum.
Botox Achieves Remarkable Sales Performance. Global sales reached $6.03 billion in 2024, with cosmetic and therapeutic sales at $2.72 billion and $3.283 billion respectively, showing growth from $5.68 billion in 2023. Regionally, North America is the largest consumer market, accounting for nearly 63% of revenue share in 2024, while Europe holds approximately 16%.
Its performance in the Chinese market has also been outstanding, with sales reaching nearly 3 billion RMB in 2022, increasing by approximately 20% year-on-year. Relying on its first-mover advantage, product quality, and brand recognition, Botox has consistently ranked first in the Chinese Type A botulinum toxin market share and also dominates the global botulinum toxin market, with sales continuing to rise.
Following this legal defeat, Revance is required to pay AbbVie $56 million in patent royalties, accounting for nearly 67% of Daxxify®'s 2023 sales revenue, which will undoubtedly place significant strain on the company’s cash flow and short-term profitability.
However, even with the patent fees, if Daxxify's long-lasting advantage is widely accepted by the market and captures a sufficient share, Revance still has room to survive. But the $56 million bill undoubtedly raises its profitability threshold significantly.
Before the main patent of Botox expires around 2028, AbbVie's victory in this case can not only delay the impact of strong competitors but also further consolidate the company's leading position in the botulinum toxin market.
Overall, this case also serves as a wake-up call for all biotech companies attempting to enter fields dominated by patent giants: while innovation is crucial, navigating around dense patent networks and preparing for potential legal ambushes are unavoidable life-or-death challenges.
Source: FIERCE Pharma